Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Synfacts 2023; 19(10): 1037
DOI: 10.1055/s-0042-1752791

Innovative Drug Discovery and Development

Contributor(s):

Antonia F. Stepan (Roche)

,

Jacob W. Greenwood (MSD)

process chemistry - nitrosamines - mutagenic impurities - in silico risk assessment - Mirabilis

Article published online:
14 September 2023

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany